Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-297.76%
operating margin TTM
-326.56%
revenue TTM
33.57 Million
revenue per share TTM
0.41$
valuation ratios | |
|---|---|
| pe ratio | -4.51 |
| peg ratio | -0.28 |
| price to book ratio | 2.00 |
| price to sales ratio | 8.83 |
| enterprise value multiple | -2.87 |
| price fair value | 2.00 |
profitability ratios | |
|---|---|
| gross profit margin | 94.83% |
| operating profit margin | -326.56% |
| pretax profit margin | -297.41% |
| net profit margin | -297.76% |
| return on assets | -31.56% |
| return on equity | -50.68% |
| return on capital employed | -37.74% |
liquidity ratios | |
|---|---|
| current ratio | 9.00 |
| quick ratio | 9.00 |
| cash ratio | 2.25 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 0.00 |
| operating cycle | 30.19 |
| days of payables outstanding | 156.66 |
| cash conversion cycle | -126.47 |
| receivables turnover | 12.09 |
| payables turnover | 2.33 |
| inventory turnover | 0.00 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.18 |
| debt equity ratio | 0.25 |
| long term debt to capitalization | 0.00 |
| total debt to capitalization | 0.20 |
| interest coverage | 0.00 |
| cash flow to debt ratio | -1.63 |
cash flow ratios | |
|---|---|
| free cash flow per share | -0.76 |
| cash per share | 1.87 |
| operating cash flow per share | -0.76 |
| free cash flow operating cash flow ratio | 1.01 |
| cash flow coverage ratios | -1.63 |
| short term coverage ratios | -14.62 |
| capital expenditure coverage ratio | -142.11 |
Frequently Asked Questions
When was the last time C4 Therapeutics, Inc. (NASDAQ:CCCC) reported earnings?
C4 Therapeutics, Inc. (CCCC) published its most recent earnings results on 12-05-2026.
What is C4 Therapeutics, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. C4 Therapeutics, Inc. (NASDAQ:CCCC)'s trailing twelve months ROE is -50.68%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. C4 Therapeutics, Inc. (CCCC) currently has a ROA of -31.56%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did CCCC's net profit margin stand at?
CCCC reported a profit margin of -297.76% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is CCCC's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 9.00 in the most recent quarter. The quick ratio stood at 9.00, with a Debt/Eq ratio of 0.25.